Paper42583201
Dose-escalated twice daily radiotherapy for limited stage small cell lung cancer: an implementation strategy in the Netherlands.
Bosch F and 7 others. J Thorac Dis, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Dose-escalated twice daily radiotherapy for limited stage small cell lung cancer: an implementation strategy in the Netherlands. Papers, record 42583201. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42583201
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Dose-escalated twice daily radiotherapy for limited stage small cell lung cancer: an implementation strategy in the Netherlands.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment on | 41660477 | BID-ding wars: will dose-escalated twice daily radiotherapy for limited stage small cell lung cancer be the new standard of care?-critical analysis of the literature. | https://conductscience.org/library/papers/41660477 |
Source PubMed
References9
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28642008 | Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. | Lancet Oncol | 2017 | https://conductscience.org/library/papers/28642008 | PubMed |
| 2 | 39638533 | Time to escalate quality assurance in small-cell lung cancer radiotherapy trials. | Lancet Respir Med | 2024 | https://conductscience.org/library/papers/39638533 | PubMed |
| 3 | 41660477 | BID-ding wars: will dose-escalated twice daily radiotherapy for limited stage small cell lung cancer be the new standard of care?-critical analysis of the literature. | J Thorac Dis | 2026 | https://conductscience.org/library/papers/41660477 | PubMed |
| 4 | 38583494 | Evaluation of Radiation Therapy Treatment Plans in a Randomized Phase 2 Trial Comparing 2 Schedules of Twice-Daily Thoracic Radiation Therapy in Limited Stage Small Cell Lung Cancer. | Int J Radiat Oncol Biol Phys | 2024 | https://conductscience.org/library/papers/38583494 | PubMed |
| 5 | 40258573 | High-Dose Versus Standard-Dose Twice-Daily Thoracic Radiotherapy in Limited-Stage SCLC: Final Survival Data, Long-Term Toxicity, and Relapse Patterns in a Randomized, Open-Label, Phase II Trial. | J Thorac Oncol | 2025 | https://conductscience.org/library/papers/40258573 | PubMed |
| 6 | 41932500 | ESTRO-EORTC expert guideline on target delineation and radiotherapy details for stage I-III small cell lung cancer. | Radiother Oncol | 2026 | https://conductscience.org/library/papers/41932500 | PubMed |
| 7 | 36623230 | High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538. | J Clin Oncol | 2023 | https://conductscience.org/library/papers/36623230 | PubMed |
| 8 | 39146944 | High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial. | Lancet Respir Med | 2024 | https://conductscience.org/library/papers/39146944 | PubMed |
| 9 | 39268857 | Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer. | N Engl J Med | 2024 | https://conductscience.org/library/papers/39268857 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42583201
GET https://conductscience.org/api/papers/v1/42583201/authors